Osprey Private Wealth LLC Has $10.10 Million Position in Thermo Fisher Scientific Inc. $TMO

Osprey Private Wealth LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,537 shares of the medical research company’s stock after acquiring an additional 1,397 shares during the quarter. Thermo Fisher Scientific comprises 2.9% of Osprey Private Wealth LLC’s holdings, making the stock its 10th largest position. Osprey Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $10,095,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Assetmark Inc. boosted its position in shares of Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after acquiring an additional 7,023 shares during the period. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific during the fourth quarter worth about $7,505,000. EdgePoint Investment Group Inc. boosted its holdings in Thermo Fisher Scientific by 5.0% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 1,388,662 shares of the medical research company’s stock valued at $673,529,000 after purchasing an additional 65,597 shares during the period. Confluence Investment Management LLC grew its position in shares of Thermo Fisher Scientific by 14.2% during the 4th quarter. Confluence Investment Management LLC now owns 95,064 shares of the medical research company’s stock worth $55,085,000 after purchasing an additional 11,841 shares in the last quarter. Finally, Focus Partners Wealth increased its holdings in shares of Thermo Fisher Scientific by 1.2% during the third quarter. Focus Partners Wealth now owns 258,747 shares of the medical research company’s stock worth $125,514,000 after purchasing an additional 2,947 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TMO. Royal Bank Of Canada set a $490.00 price target on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. Barclays dropped their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Morgan Stanley reissued an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. DZ Bank initiated coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective for the company. Finally, Weiss Ratings downgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $602.14.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded up $2.01 during mid-day trading on Friday, reaching $526.72. The company had a trading volume of 1,233,008 shares, compared to its average volume of 1,993,707. The business has a fifty day simple moving average of $478.23 and a 200 day simple moving average of $516.44. The company has a market cap of $195.74 billion, a P/E ratio of 28.96, a P/E/G ratio of 2.32 and a beta of 0.87. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $403.36 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter last year, the business posted $5.15 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.